Figure 4: Elevated RIG-I inhibits proliferation in pancreatic β cell line.
From: RIG-I inhibits pancreatic β cell proliferation through competitive binding of activated Src
(A) Min6 cells were treated with the indicated concentrations (0, 1, 5, 10, 20, 50 and 100 μM) of retinoic acid (RA) for the indicated times (6 h, 12 h and 24 h) and stimulated with IGF-1 (10 nM). Cell viability was assessed by the MTT assay. 24 hours after transfection of a plasmid encoding RIG-I, Min6 cells were treated with IGF-1 and RA as indicated. (B) DNA synthesis was analysed using EdU labelling assays. Representative micrographs of EdU labelling assays in MIN6 cells are shown (scale bar = 120 μm). The percentage of EdU-positive β cells was quantified. Flow cytometric assays were performed to calculate the percentages of MIN6 cells at the (C) G1 phase and (D) S phase. (E) After transfection of si-RIG-I for 24 h, Min6 cells were treated with RA. DNA synthesis was analysed using EdU labelling assays. Representative micrographs of EdU labelling assays in MIN6 cells are shown (scale bar = 120 μm). The percentage of EdU-positive β cells was quantified. Data are means ± SEM of three separate experiments. *P < 0.05 versus control.
